SCHEMBL10147677

SCHEMBL10147677

CCOC(=O)C(=O)CC(=O)c1c(C)cc(C)cc1OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
FFAR4 Q5NUL3 1/20 0.44
NR1H4 Q96RI1 1/20 0.43
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
POLB P06746 1/20 0.42
LMNA P02545 2/20 0.41
MRGPRX4 Q96LA9 2/20 0.41
NPC1 O15118 1/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PTGER1 P34995 1/20 0.40
PTGER4 P35408 1/20 0.40
PTGER3 P43115 1/20 0.40
PTGER2 P43116 1/20 0.40
TACR1 P25103 1/20 0.40
RXRA P19793 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10147482 0.81 CYP19A1 (0.46) ALDH1A1KDM4EMAPTPOLBLMNA
SCHEMBL26666325 0.80 LRRK2 (0.52) ALDH1A1FFAR4NR1H4KDM4EMAPT
SCHEMBL7215600 0.79 SMN1; SMN2 (0.47) ALDH1A1KDM4EMAPTPOLBLMNA
SCHEMBL69725 0.79 SGMS2 (0.52) ALDH1A1NR1H4MAPTLMNANPC1
SCHEMBL30535266 0.79 SGMS2 (0.52) ALDH1A1NR1H4MAPTLMNANPC1
SCHEMBL10147678 0.79 MAPT (0.51) FFAR4MAPTMRGPRX4SMN1; SMN2MEN1
SCHEMBL3956579 0.78 ALDH1A1 (0.47) ALDH1A1FFAR4NR1H4KDM4ELMNA
SCHEMBL7911106 0.78 ALDH1A1 (0.55) ALDH1A1NR1H4LMNANPC1RAB9A
SCHEMBL12939113 0.77 NR1H4 (0.46) ALDH1A1FFAR4NR1H4POLBLMNA
SCHEMBL19766826 0.77 MCL1 (0.47) ALDH1A1FFAR4NR1H4KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993556-B2 Resorcinol derivatives as HSP90 inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-03-31 US disclosed
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90AB2P ALDH1A1 1996/4885FFAR4 4764/4885NR1H4 873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.